Developers rely on a battery of supporting analytical methods and assays to be able to make informed decisions and to help decrease uncertainty and lower failure rates and even to gather the information that cannot or would not be generated experimentally. As we are in an era in medicine where the “one drug fits all” is being replaced by custom-made personalized medicine and new ultra-sensitive non-invasive diagnostic procedures, the volume and variety of information generated during drug development have increased tremendously.
Relevant data is needed not only for leveraging an understanding of a drug, a disease, and how a drug affects the human body, as well as show how the body responds to the drug, but also in order to enable scientific and informed decision-making in the development of new innovative therapies. It is becoming even more imperative to identify and quantify targets and biomarkers that can characterize the efficacy and safety at different stages of drug development.
Being able to explore and integrate biomarkers from preclinical and clinical studies for multiple compounds can help identify poor candidates early, and in turn, reduce the time and cost of development. The knowledge and information provided by analytical tools can aid the selection of the right dosing, duration, and patient population - and increase the probability of success.
At Svar Life Science we have the products, tools, and services that enable more informed decision-making, and help reduce uncertainty when moving between phases of development. We can help you make your decisions faster and better and with our help, you can fast forward your drug development program.
Book a free consultation with us to speak to one of our scientific experts and find out how we can help you plan for your drug development initiatives.